Wei Xinkang (603676.SH): Some directors and senior management plan to reduce their share holdings
Ge Longhui, May 21丨Wei Xinkang (603676.SH) announced that due to personal capital requirements, Mr. Liu Feng plans to reduce the number of company shares held by no more than 954,280 shares through centralized bidding on the Shanghai Stock Exchange within 3 months after 15 trading days from the date of disclosure of this announcement, with a reduction ratio of no more than 0.22% of the company's total shares; due to personal capital requirements, Ms. Liu Binbin plans to reduce the company's holdings through centralized bidding on the Shanghai Stock Exchange within 3 months after 15 trading days from the disclosure of this announcement The number of shares shall not exceed 221,
Wei Xinkang (603676.SH): Does not involve synthetic biotechnology
Gelonghui, May 9丨Wei Xinkang (603676.SH) said on the investor interactive platform that the company's main business is R&D, production, and sales of chemical preparations and their APIs, and is currently not involved in synthetic biotechnology.
Weixinkang (603676.SH) subsidiary obtained drug registration certificate for potassium aspartate injection
Zhitong Finance App News, Wei Xinkang (603676.SH) issued an announcement. Recently, Yangpu Jingtai Pharmaceutical Co., Ltd. (“Yangpu Jingtai”), a wholly-owned subsidiary of the company, received the “Drug Registration Certificate” for potassium aspartate injections approved and issued by the State Drug Administration. Potassium aspartate injection is an electrolyte supplement. It is used for hypokalemia caused by various causes. This product can be used to supplement potassium when the following symptoms or conditions occur: when combined with antihypertensive diuretics, adrenocortical hormones, cardiac glycosides, insulin, or certain antibiotics; low-potassium periodic limb paralysis; hypokalemia in the case of heart disease
Wei Xinkang (603676.SH) announced first-quarter results, net profit of 94.914,700 yuan, an increase of 57.54% year-on-year
Wei Xinkang (603676.SH) released its report for the first quarter of 2024. During the reporting period, the company achieved operating income of 3...
Wei Xinkang (603676.SH): Received 41.8641 million yuan in government grants
Gelonghui, March 29丨Wei Xinkang (603676.SH) announced that Tibet Zhongwei Chengkang Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, received 418.64,100 yuan in government subsidies related to revenue, accounting for 23.66% of the company's 2022 audited net profit attributable to shareholders of listed companies.
[Instant Analysis of BT Financial Report] Wei Xinkang 2023 Third Quarter Report: Net profit increased significantly, balance ratio declined, and net operating cash flow decreased
Announcement time of this financial report: 2023-10-24 16:07:53 Wei Xinkang (stock code: 603676) is a comprehensive pharmaceutical enterprise, mainly engaged in pharmaceutical R&D, production and sales. According to earnings data for the third quarter of 2023, there are some notable changes in the company's operating conditions and financial performance. First, in terms of assets and liabilities, Wei Xinkang's total assets reached 1,772 billion yuan at the end of this reporting period, up from 1,665 billion yuan at the end of the previous year. Total liabilities at the end of this reporting period were $428 million, compared to 444 million yuan at the end of the previous year
Wei Xinkang (603676.SH): Net profit for the third quarter was 76.2395 million yuan, up 58.78% year on year
Glonghui, Oct. 24, 丨 Wei Xinkang (603676.SH) announced its report for the third quarter of 2023. Revenue for the reporting period was 312 million yuan, down 21.89% year on year; net profit attributable to shareholders of listed companies was 76.2395 million yuan, up 58.78% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was RMB 38.646 million, down 18.30% year on year; basic earnings per share were 0.18 yuan/share.
Wei Xinkang (603676.SH): Currently not involving drugs related to the prevention of Mycoplasma pneumoniae infection
Glonghui, Oct. 19, 丨 Wei Xinkang (603676.SH) said on the investor interactive platform that the company's main products cover vitamins, trace elements, electrolytes, etc. in parenteral nutritional drugs; there are currently no drugs related to preventing Mycoplasma pneumoniae infection.
Wei Xinkang (603676.SH) subsidiary obtained a multi-vitamin injection (13) (10/3) drug registration certificate
Wei Xinkang (603676.SH) issued an announcement. Recently, Tibet Zhongwei Chengkang Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company...
GLONGHUI ANNOUNCEMENT SELECTION | Sanhua Intelligent Control: Net profit increased by 3903% in the first half of the year to 1,395 million yuan and plans to distribute 0.5 yuan in 10; Lianying Medical: plans to spend 400 million yuan to 800 million yuan t
[Performance Focus] Rambler (002351.SZ): Net profit increased 64.51% in the first half of the year to 174 million yuan Rambler (002351.SZ) announced its 2023 semi-annual report. Operating income for the reporting period was 1,189 million yuan, up 19.42% year on year; net profit attributable to shareholders of listed companies was 174 million yuan, up 64.51% year on year; net profit attributable to shareholders of listed companies was 168 million yuan, up 90.35% year on year; basic earnings per share were 0.20 yuan. Xinhua Healthcare (600587.SH): Net profit for the first half of the year 4.
Wei Xinkang (603676.SH): Net profit for the first half of the year was 134 million yuan, up 30.13% year on year
Glonghui, August 22: Wei Xinkang (603676.SH) announced its 2023 semi-annual report. During the reporting period, it achieved operating income of 749 million yuan, an increase of 12.18%; net profit attributable to shareholders of listed companies was 134 million yuan, up 30.13% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 131 million yuan, an increase of 29.32% over the previous year; and basic earnings per share of 0.31 yuan.
Wei Xinkang (603676.SH): Service revenue mainly comes from cooperative products such as injectable multivitamin (12) and sucrose iron injections
On July 31, GLONGHUI|WEI Xinkang (603676.SH) recently said in response to a survey from institutional investors that service revenue is mainly patent and technology usage fees, trademark/brand usage fees, market management and promotion service fees charged to partners. After the implementation of the “two-ticket system”, since some products produced cooperatively could not be sold by the company, the cooperative manufacturer sold and shipped the cooperative products produced to designated pharmaceutical distribution enterprises according to the company's orders. The company dominated the entire market management and promotion service business. The company charged technology usage fees, trademark usage fees, market management and promotion from the cooperative manufacturers
Wei Xinkang (603676.SH): Most of the company's products are exclusive domestic products or exclusive domestic varieties, which do not meet the requirements for national procurement
On July 31, GLONGHUI|WEI Xinkang (603676.SH) recently said in response to a survey from institutional investors that according to the latest national collection rules, 1 original research company and 3 generic drugs that have passed the consistency evaluation meet the national collection conditions. Most of the company's products are exclusive domestic products or exclusive domestic varieties, which do not meet the conditions for national procurement yet. Some provinces have issued collection policy documents. The company is actively responding, seeking more market opportunities and achieving sustainable and stable development.
Wei Xinkang (603676.SH): The Market Management Center has three organizational modules: sales team, functional departments, and compliance system
In response to a recent survey from institutional investors, GLONGHUI (603676.SH) stated that the company's market management center has three organizational modules: sales team, functional department, and compliance system. Among them, the sales team has a division system as the core and is divided into the first division, platform division, and new product division according to the products and components they are responsible for.
Wei Xinkang: 10 million yuan of financial products due to redemption financial income of about 78800 yuan
Wei Xinkang (603676) announced that Inner Mongolia Baiyi Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, purchased RMB 10 million for the 12th phase of the 2021 linked exchange rate structural deposit issued by China Everbright Bank Co., Ltd. Beijing Branch on December 17, 2021. The financial product has expired on March 17, 2022. The company recovered the principal of RMB 10 million and obtained a product income of RMB 78800. The principal and income were received on March 17, 2022 and transferred to the special fund-raising account.
Wei Xinkang: expansion of core products and gradual expansion of new products net profit in 2021 is expected to increase by 50% to 75% compared with the same period last year.
Wei Xinkang (603676) issued a performance forecast that the company expects the net profit attributed to shareholders of listed companies to increase by 29.2124 million yuan to 43.8186 million yuan in 2021 compared with the same period last year, an increase of 50% to 75% compared with the same period last year. During the reporting period, the business scale of the company's core product multivitamin (12) for injection expanded, and the company's new products, such as children's multivitamin injection (13), a variety of trace element injection and other products gradually increased, resulting in the growth of the company's performance.
Wei Xinkang: it is estimated that the net profit attributable to 2021 is 87.6372 million yuan to 102 million yuan, an increase of 50% to 75% over the previous year.
Wei Xinkang issued a performance forecast on 2022-01-21. It is estimated that the net profit attributable to 2021 is 87.6372 million yuan to 102 million yuan, an increase of 50% to 75% over the previous year. The reasons for this performance change are as follows: during the reporting period, the business scale of the company's core product multivitamin (12) for injection expanded, and the company's new products, such as children's multivitamin injection (13), a variety of trace element injection and other products gradually increased, which led to the growth of the company's performance. The company continues to cultivate carefully in the sales channel, the core products have been precipitated and formed a certain industry dominant position and market influence. Health
Wei Xinkang's latest announcement: net profit in 2021 is 50% more than the same period last year. 75%.
Wei Xinkang announced that the net profit attributed to shareholders of listed companies in 2021 is expected to increase by 29.2124 million yuan to 43.8186 million yuan compared with the same period last year, an increase of 50%, 75%, compared with the same period last year. The chairman of the company is Zhang Yong. Mr. Zhang Yong: born in 1972, Chinese nationality, no permanent residence abroad, master's degree, graduated from Shenyang Pharmaceutical University in 1993, graduated from Changjiang Business School in 2012, received a master's degree in business administration. Executive director and general manager of Wei Xinkang and its subsidiaries from 2002 to 2015; from 2015 to now
Wei Xinkang: GF Securities Co., LTD. investigated our company on January 14th.
Wei Xinkang (603676) issued a notice on January 17, 2022, saying: GF Securities Co., LTD. and Li Anfei investigated our company on January 14, 2022. The main content of this survey: Q: what is the company's sales model? What is the business team like? Answer: the company implements the regional terminal distribution system, with fewer production approvals and competitive products in the domestic market, with strong market competitiveness and the right to select regional terminal distributors and regional promoters. According to the characteristics of the products, the company selects strong regional terminal distributors with GSP certification qualifications to build a sales network covering the whole country, which will be distributed by regional terminals.
Wei Xinkang: Taikang Asset Management Co., Ltd. investigated our company on January 13.
Wei Xinkang (603676) issued a notice on January 13, 2022, saying: tu Jian, Liu Xiaofeng and Yan Yuan of Taikang Asset Management Co., Ltd. investigated our company on January 13, 2022. The main content of this survey: Q: 12 dimensions currently account for 90% of the share, is there any risk of collection and mining? A: the national collection is a generic drug that passes the consistency evaluation. Through the consistency evaluation of drugs, whether the national organization can trigger the collection of detailed rules, is basically the original research and development of generic drugs through the consistency evaluation, so that the three have the possibility to be included in the collection. At present, there are 2 products with the same common name in 12 dimensions. Q:
No Data